Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 9 of 26 · 1221 articles
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...
The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...
The paper describes a new nanodelivery method that improves targeted delivery of 5‑ASA in preclinical models, which could eventually address limitations of oral mesalazine formulations for colonic inflammation.
If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
This trial tests a new oral drug for moderate to severe ulcerative colitis with a short (12-week) primary endpoint; people with active UC may be interested in emerging treatment options and clinical trial opportunities.
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
Label changes affect how balsalazide is prescribed and monitored for people with ulcerative colitis. The update highlights safety risks—especially kidney, liver, and hypersensitivity concerns—and reinforces age- and...
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...
If confirmed, differences between tirzepatide and GLP-1RAs could influence medication choice for people with IBD who need weight-loss or glucose-lowering therapy. Reduced IV steroid use suggests fewer severe flares...
Cure8 found this source from Intestinal research, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Azathioprine, and Immunomodulators. Open the original article for the full...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.
People with IBD (ulcerative colitis or Crohn’s/regional enteritis) may develop vitamin K–related hypoprothrombinemia; this updated label describes when and how vitamin K (phytonadione) is used and emphasizes INR...
Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.
Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.
The study identifies blood gene-expression patterns linked to response to TNF-alpha inhibitors and highlights overlap between psoriasis and IBD, which could point to shared biomarkers or mechanisms relevant to treatment...
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
The paper presents a validated lab method to detect and quantify enantiomeric impurities in upadacitinib, which supports drug quality and safety for patients treated with JAK‑1 inhibitors for IBD and other conditions.
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Patients with hidradenitis suppurativa have higher baseline IBD risk, and IL-17 inhibitors are effective HS treatments. People with Crohn’s disease or ulcerative colitis (or those at risk) may worry whether these drugs...
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
Trends in treatments for children with IBD can affect hospitalization and surgical needs. Noting rising use of biologics (infliximab) alongside fewer hospitalizations may be important for families and clinicians tracking...
This trial describes a large Phase 3 extension study collecting long-term safety and tolerability data for tulisokibart (MK-7240), an investigational TL1A-targeting antibody for Crohn’s disease and ulcerative colitis....
This trial tests an oral live biotherapeutic (MH002) aimed at restoring a healthier gut microbiome in people with mild-to-moderate ulcerative colitis. If effective and safe, it would offer a non-immunosuppressive,...
Thalidomide can help treat refractory pediatric IBD but causes peripheral neuropathy. Knowing a cumulative-dose threshold linked to neuropathy could help clinicians balance benefit and neurotoxicity risk.
The study describes a targeted oral delivery system for 5-ASA that aims to concentrate drug release in the colon and also leverage inulin’s prebiotic/immunomodulatory properties—potentially improving effectiveness and...
This trial tests standardized encapsulated fecal microbiota products as a microbiome-directed therapy for active Crohn’s disease, focusing on whether donor microbes engraft in the ileum and colon and whether that relates...
Malnutrition and growth failure at diagnosis are common in children with IBD—especially Crohn’s—and can indicate higher inflammatory burden. Monitoring and addressing nutrition and growth is important because most...
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...
Nurse-led, protocolized care can make delivery of complex biologic and small-molecule IBD treatments safer and more consistent.
Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...
If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment...
The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.
Patients with CGD can develop an IBD-like condition that is hard to treat because many immunosuppressive drugs raise infection risk. This trial suggests thalidomide may reduce intestinal inflammation in CGD-IBD without...
Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can...
A controlled trial found low-dose naltrexone did not induce endoscopic or clinical remission in Crohn's disease, but it showed a possible benefit for reducing fatigue. Patients seeking symptom relief without...
The project targets patients with refractory IBD who lack effective options; a new allogeneic stromal cell therapy could expand treatment choices for people who fail multiple drugs. The work focuses on immune pathways...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
Pregnant people with IBD or other autoimmune diseases often face tough choices about continuing biologics or JAK inhibitors. CARE-HP aims to produce broader, disease-specific evidence to help patients and clinicians...
